Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

1.095 -0.095 (-7.98%)
Streaming Delayed Price Updated: 2:12 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Earnings Scheduled For March 27, 2025
Via Benzinga
Preview: Acumen Pharmaceuticals's Earnings
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Acumen Pharmaceuticals Earnings Preview
Via Benzinga
Acumen Pharmaceuticals's Earnings: A Preview
Via Benzinga
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024
ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Acumen Pharmaceuticals's Earnings Outlook
Via Benzinga
Acumen Pharmaceuticals's Earnings: A Preview
Via Benzinga
Why Shares of Acumen Pharmaceuticals Are Down Tuesday
The company announced a $100 million stock sale. 
Via The Motley Fool
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding. 
Via InvestorPlace
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population. 
Via InvestorPlace
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... 
Via Benzinga
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
--News Direct-- 
Via News Direct
Exposures Product Safety
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring. 
Via Benzinga
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's... 
Via Benzinga
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded mixed this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.